

## Technology Advisory Committee A Interests Register

Topic: Avalglucosidase alfa for treating Pompe disease [ID3737]

Publication Date: 24/08/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Robin Lachmann	Clinical expert	Direct financial and non-financial	Dr Lachmann has received honoraria for speaking and travel expenses from Sanofi Genzyme. He has also received consulting fees from Sanofi Genzyme related to olipudase alfa for acid sphingomyelinase deficiency and has received consulting fees from Biomarin and Takeda related to their gene therapy programme for phenylketonuria. Dr Lachmann has received honoraria for speaking from Amicus.	N/A	27.10.2021	N/A	It was agreed that his declarations would not prevent Dr Lachmann from providing expert advice to the committee.
Professor Mark Eldon Roberts	Clinical expert	Direct financial	Professor Roberts has received honoraria for presentations and advisory boards for Sanofi and has worked with other companies in this field (Amicus, Audentes, Spark Therapeutics). He was a principal investigator in the	N/A	03.05.2022	N/A	It was agreed that his declarations would not prevent Professor Eldon Roberts from providing expert advice to the committee.

			clinical trials including the COMET study.				
Baroness Celia Thomas	Patient expert	Indirect financial	<p>Baroness Thomas declared indirect financial interests as her nominating organisations received the following funding:</p> <p>Association for Glycogen Storage Disease UK (AGD) has received funding from Sanofi Genzyme for on-line conference series, patient education, benefits support, and community services.</p> <p>Muscular Dystrophy UK (MDUK) has received funding from Sanofi as a sponsorship for a translational research conference</p> <p>Baroness Thomas is also a Trustee of MDUK.</p>	N/A	18.10.2021	N/A	It was agreed that her declarations would not prevent Baroness Thomas from providing expert advice to the committee
Dr James Davison	Clinical expert	Direct financial and non-financial	<p>Dr Davison is principal investigator on open clinical trials of avalglucosidase alfa ("Mini-COMET" study) and chief investigator on a forthcoming clinical trial of the same product (Baby COMET study) and associated observational studies, for which Sanofi is the study</p>	N/A	01.12.2021	N/A	It was agreed that his declarations would not prevent Dr Davison from providing expert advice to the committee.

			sponsor. He attended an advisory board in another area for Sanofi. He has attended various advisory bodies and symposia and is a member of the policy working group with NHS England reviewing doses of the current treatment.				
--	--	--	--	--	--	--	--